WOCKPHARMA2023-07-012023-09-30 WOCKPHARMA2023-07-012023-09-30 WOCKPHARMA2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2023-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2023-04-01 2024-03-31 2023-11-14 2023-11-06 INR Crores Half yearly 11:30:00 14:00:00 2023-11-14 2023-11-14 true Cash Flow Indirect Not applicable Single segment Pharmaceuticals 2023-07-01 2023-09-30 Unaudited Standalone 2600000000.00 60000000.00 2660000000.00 510000000.00 410000000.00 130000000.00 630000000.00 590000000.00 440000000.00 1020000000.00 3730000000.00 -1070000000.00 0.00 -1070000000.00 0.00 0.00 0.00 0.00 -1070000000.00 0.00 0.00 0.00 0.00 -1070000000.00 0.00 -1070000000.00 0.00 0.00 720000000.00 5 -7.39 -7.39 0.00 0.00 -7.39 -7.39 0.00 0.00 0.00 1. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 14, 2023. The results have been subjected to limited review by the Statutory Auditors of the Company. 2. (a)The Company had accounted for a contract asset of Rs. 50 crores pursuant to a contract manufacturing agreement. The Customer is yet to fulfil its contractual obligations and commitments. Though, the Company is pursuing various options and taking necessary actions related to this matter, given the uncertainty, The Company had provided for this contract asset and had disclosed it as 'Exceptional items'during previous year. The Company had also purchased certain specific inventory for this contract which has not been used. The Company is continuing to evaluate alternate options to liquidate/ utilize such inventory, pending which, during the previous quarter, the Company has made a provision of Rs 14 crores for such inventory basis the current assessment and information available as on date. This expenditure is also reported as an ‘Exceptional item’. (b)The Company had received advances for supply of goods from Wockhardt Bio AG, a majorly held foreign subsidiary of the Company, of which USD 89 million had been outstanding as at March 31, 2022.  In accordance with the direction of Reserve Bank of India (RBI) / Authorised Dealer (AD) Bank, such advances were supposed to be adjusted only against supply of goods by the Company. Accordingly, this  advance amount received was accounted at the historical transaction exchange rate in accordance with Ind AS 21- 'The Effects of Changes in Foreign Exchange Rates'   The Company, as part of normal business, had also been providing services including but not limited to R&D services and assignment of rights over its new chemical entities (NCE) to the aforesaid foreign subsidiary and had outstanding receivables of USD 113 million.  Since the Company had not been able to supply the goods, the Company received an approval from RBI/ AD on March 10, 2023, for adjustment of the aforesaid advance with these outstanding receivables. Pursuant to this, Company had recognised an exchange loss of Rs. 185 crore on the settlement of the advance and receivables of USD 89 million under 'Exceptional items' during the previous year. Given that these receivables and advance liability are eliminated on consolidation, this settlement did not have any impact on the consolidated financial results of the Group for the previous period. 3.During the quarter ended September 30, 2023 , the Company has allotted Nil( Year to date: 6,250) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options. 4. The Company is exclusively into Pharmaceutical business Segment. Single segment 2023-04-01 2023-09-30 Unaudited Standalone 5110000000.00 120000000.00 5230000000.00 1130000000.00 760000000.00 190000000.00 1260000000.00 1170000000.00 880000000.00 1920000000.00 7310000000.00 -2080000000.00 -140000000.00 -2220000000.00 0.00 0.00 0.00 0.00 -2220000000.00 0.00 0.00 0.00 0.00 -2220000000.00 10000000.00 -2210000000.00 0.00 0.00 720000000.00 5 -15.40 -15.40 0.00 0.00 -15.40 -15.40 0.00 0.00 0.00 Other Expenses 1020000000.00 Other Expenses 1920000000.00 14770000000.00 560000000.00 0.00 0.00 580000000.00 7720000000.00 0.00 0.00 2970000000.00 0.00 0.00 610000000.00 3580000000.00 2500000000.00 1990000000.00 31700000000.00 3270000000.00 0.00 5020000000.00 40000000.00 290000000.00 0.00 1090000000.00 6440000000.00 0.00 2060000000.00 11770000000.00 1830000000.00 0.00 45300000000.00 720000000.00 14600000000.00 15320000000.00 15320000000.00 7780000000.00 0.00 2910000000.00 10690000000.00 280000000.00 0.00 0.00 0.00 10970000000.00 9200000000.00 5290000000.00 3370000000.00 17860000000.00 870000000.00 260000000.00 20000000.00 0.00 19010000000.00 0.00 0.00 29980000000.00 45300000000.00 Notes to Assets Liabilities 1. Property, Plant and Equipment of Rs. 1477 crore includes Right of use assets amounting to Rs. 341 crore. 2. Non-current Investment also includes Investments in subsidiaries. 3. Other non-current assets of Rs. 199 includes Non-current tax assets (net) amounting to Rs. 99 crore. 4. Other non-current financial liabilities consists Lease liabilities amounting to Rs. 291 crore. 5. Trade payables (current) of Rs. 529 crore, current consists of (a) Total outstanding dues of Micro enterprises and Small enterprises amounting to Rs. 34 crore and (b) Total outstanding dues of creditors other than micro enterprises and small enterprises amounting to Rs. 495 crore. 6. Other current financial liabilities of Rs. 337 crores include Lease liabilities amounting to Rs. 79 crore. 7. Non-current assets classified as held for sale represents Assets classified as held for sale. Please also, additionally refer to the Statement of Standalone Unaudited Results for the quarter and half year ended September 30, 2023 as attached to the Outcome of Board Meeting. Notes to Cash Flow Statements: 1. Adjustments for unrealised foreign exchange losses gains consists of Net foreign exchange fluctuation (gain)/Loss, net. 2. Cash inflow (outflow) of cash consists of Margin money under lien and Bank balances (other than cash and cash equilvalents) Rs. 5 Crore. 3. Proceeds from issuance of shares consists of transaction cost relating to Right Issue of Rs. 1 Crore. 4. Proceeds from borrowing consists of loan from Related Parties of Rs. 222 Crore. 5. Repayment from borrowing consists of Repayment of long term borrowings Rs. 101 Crore , Repayment of loan taken from Related Parties long term Rs. 47 Crore , Repayment of loan taken from Related Parties Short term 11 crore and short term borrowing( net ) Rs 23 crore . 6. Aggregated/ segreggated in accordance with the prescribed format and to the extent is the requirement of the accounting standard. 7. Decrease in loans and advances and other asset in row no 24 includes decrease in loans and other assets of Rs 31 crores. Please also, additionally refer to the Statement of Standalone Unaudited Results for the quarter and half year ended September 30, 2023 as attached to the Outcome of Board Meeting. 1170000000.00 220000000.00 490000000.00 0.00 310000000.00 0.00 0.00 0.00 0.00 -400000000.00 0.00 70000000.00 0.00 880000000.00 0.00 0.00 0.00 0.00 0.00 230000000.00 0.00 30000000.00 10000000.00 0.00 0.00 0.00 0.00 140000000.00 0.00 3090000000.00 870000000.00 0.00 0.00 0.00 0.00 0.00 870000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 40000000.00 0.00 0.00 0.00 300000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10000000.00 0.00 50000000.00 0.00 -280000000.00 0.00 0.00 -10000000.00 0.00 0.00 0.00 0.00 0.00 2220000000.00 1820000000.00 0.00 410000000.00 0.00 570000000.00 0.00 0.00 -590000000.00 0.00 0.00 0.00 40000000.00 40000000.00 0.00 10000000.00 0.00 0.00